AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37851732 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalization
Number of subjects: 1047
Study 37851732 — intervention group
Group type: EXPERIMENTAL
Intervention: Return to work or education
Number of subjects: 1047
Study 37851732 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent symptoms
Number of subjects: 1047
Study 37851732 — intervention group
Group type: EXPERIMENTAL
Intervention: New disabilities in instrumental activities of daily living
Number of subjects: 1047
Study 37851732 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive impairment
Number of subjects: 1047
Study 37851732 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety
Number of subjects: 1047
Study 37851732 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 1047
Study 37851732 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-traumatic stress symptoms
Number of subjects: 1047
Study 37851874 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide (160 mg) daily plus leuprolide every 12 weeks (combination group)
Number of subjects: 1068
Study 37851874 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide monotherapy (monotherapy group)
Number of subjects: 1068
Study 37851874 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus leuprolide (leuprolide-alone group)
Number of subjects: 1068
Study 37851937 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicancer early detection (MCED) tests
Number of subjects: 0
Study 37851937 — intervention group
Group type: EXPERIMENTAL
Intervention: MCED signal positive results
Number of subjects: 0
Study 37852041 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with Moebius Syndrome (MBS)
Number of subjects: 0
Study 37852041 — intervention group
Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 0
Study 37852041 — intervention group
Group type: EXPERIMENTAL
Intervention: MBS participants (fMRI analysis)
Number of subjects: 0
Study 37852041 — intervention group
Group type: COMPARATOR
Intervention: Matched controls (fMRI analysis)
Number of subjects: 0
Study 37852214 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin levels in plasma samples measured by enzyme immunoassay method
Number of subjects: 90
Study 37852214 — intervention group
Group type: COMPARATOR
Intervention: Melatonin levels in MOH patients
Number of subjects: 90
Study 37852214 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma melatonin levels
Number of subjects: 90
Study 37852261 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadonilimab 6 mg/kg once every 2 weeks
Number of subjects: 119
Study 37852306 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast 30 mg twice daily
Number of subjects: 289
Study 37852306 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 289
Study 37852328 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (4400 IU/d)
Number of subjects: 0
Study 37852328 — intervention group
Group type: COMPARATOR
Intervention: Standard prenatal multivitamin with vitamin D (400 IU/d)
Number of subjects: 0
Study 37852328 — intervention group
Group type: COMPARATOR
Intervention: Placebo alongside standard prenatal multivitamin with vitamin D (400 IU/d)
Number of subjects: 0
Study 37852531 — intervention group
Group type: EXPERIMENTAL
Intervention: 1st BIEN intervention (bilingual/bicultural intervention with Brain Injury Education and outpatient Navigation)
Number of subjects: 0
Study 37852531 — intervention group
Group type: EXPERIMENTAL
Intervention: 1st BIEN intervention
Number of subjects: 0
Study 37852530 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Living Program (HeLP)
Number of subjects: 0
Study 37852530 — intervention group
Group type: COMPARATOR
Intervention: Recommended Treatment of Obesity in Primary Care (RTOP)
Number of subjects: 0
Study 37852649 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin
Number of subjects: 4400
Study 37852649 — intervention group
Group type: COMPARATOR
Intervention: atorvastatin
Number of subjects: 4400
Study 37852737 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (480 mg) and metformin (1000 mg, orally, twice daily after a 14-day lead-in phase)
Number of subjects: 24
Study 37852737 — intervention group
Group type: COMPARATOR
Intervention: Metformin alone
Number of subjects: 24
Study 37852742 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline lower retinal capillary blood flow in the superior retina
Number of subjects: 112
Study 37852765 — intervention group
Group type: EXPERIMENTAL
Intervention: Subthreshold micropulse laser (SML)
Number of subjects: 266
Study 37852765 — intervention group
Group type: COMPARATOR
Intervention: Standard laser (SL)
Number of subjects: 266
Study 37852774 — intervention group
Group type: EXPERIMENTAL
Intervention: MyCog paradigm (iPad-based, self-administered cognitive assessment)
Number of subjects: 45257
Study 37852774 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 45257
Study 37852774 — intervention group
Group type: EXPERIMENTAL
Intervention: MyCog paradigm
Number of subjects: 45257
Study 37852850 — intervention group
Group type: EXPERIMENTAL
Intervention: avelumab + axitinib
Number of subjects: 412
Study 37852850 — intervention group
Group type: COMPARATOR
Intervention: sunitinib
Number of subjects: 412
Study 37853118 — intervention group
Group type: EXPERIMENTAL
Intervention: Oncolytic immunotherapy
Number of subjects: 0
Study 37853118 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 37853163 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal intubation
Number of subjects: 62
Study 37853163 — intervention group
Group type: COMPARATOR
Intervention: Oral intubation
Number of subjects: 62
Study 37853279 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity troponin T (hsTnT) measurement
Number of subjects: 442
Study 37853333 — intervention group
Group type: EXPERIMENTAL
Intervention: eMB (Mothers and Babies Online Course)
Number of subjects: 30
Study 37853333 — intervention group
Group type: COMPARATOR
Intervention: Control group (list of community resources)
Number of subjects: 30
Study 37853343 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian Predictive Probability approach
Number of subjects: 0
Study 37853343 — intervention group
Group type: EXPERIMENTAL
Intervention: O'Brien-Fleming approach
Number of subjects: 0
Study 37853343 — intervention group
Group type: EXPERIMENTAL
Intervention: Haybittle-Peto approach
Number of subjects: 0
Study 37853343 — intervention group
Group type: EXPERIMENTAL
Intervention: Group sequential approaches
Number of subjects: 0
Study 37853343 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian approaches
Number of subjects: 0
Study 37853343 — intervention group
Group type: COMPARATOR
Intervention: Fixed design
Number of subjects: 0
Study 37853351 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized decision support system (CDS)
Number of subjects: 1145
Study 37853351 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 1145
Study 37853370 — intervention group
Group type: EXPERIMENTAL
Intervention: B. infantis Rosell®-33 supplementation during the first month of life
Number of subjects: 200
Study 37853370 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 37853420 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave therapy
Number of subjects: 150
Study 37853420 — intervention group
Group type: EXPERIMENTAL
Intervention: Myofascial release therapy
Number of subjects: 150
Study 37853420 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (extracorporeal shockwave therapy + myofascial release therapy)
Number of subjects: 150
Study 37853420 — intervention group
Group type: COMPARATOR
Intervention: N/A (Control group not specified)
Number of subjects: 150
Study 37853427 — intervention group
Group type: EXPERIMENTAL
Intervention: Saliva-based SARS-CoV-2 screening testing
Number of subjects: 23
Study 37853427 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 screening testing
Number of subjects: 23
Study 37853427 — intervention group
Group type: EXPERIMENTAL
Intervention: Clear communication of school policies and mitigation strategies
Number of subjects: 23
Study 37853454 — intervention group
Group type: EXPERIMENTAL
Intervention: H3K27M-vac vaccine administered with standard radiotherapy (RT) and atezolizumab (ATE)
Number of subjects: 15
Study 37853485 — intervention group
Group type: EXPERIMENTAL
Intervention: OptiCogs intervention
Number of subjects: 9
Study 37853490 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein dose (≥ 2.2 g/kg body weight/day)
Number of subjects: 312
Study 37853490 — intervention group
Group type: COMPARATOR
Intervention: Usual protein dose (≤ 1.2 g/kg body weight/day)
Number of subjects: 312
Study 37853560 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenapanor
Number of subjects: 0
Study 37853560 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 37853605 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive adherence counselling (IAC) - three once-monthly sessions
Number of subjects: 136
Study 37853605 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (non-intervention arm)
Number of subjects: 136
Study 37853676 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.002% omidenepag isopropyl (OMDI) once daily in both eyes for 3 months
Number of subjects: 107
Study 37853731 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP awareness and education
Number of subjects: 27
Study 37853826 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest quartile of global cognition z-scores
Number of subjects: 11675
Study 37853826 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest quartile of factor scores
Number of subjects: 11675
Study 37853826 — intervention group
Group type: EXPERIMENTAL
Intervention: Global cognition z-scores
Number of subjects: 11675
Study 37853826 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor scores
Number of subjects: 11675
Study 37854684 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated MRgRT
Number of subjects: 80
Study 37854715 — intervention group
Group type: EXPERIMENTAL
Intervention: efzofitimod
Number of subjects: 0
Study 37854807 — intervention group
Group type: EXPERIMENTAL
Intervention: Stented cryopreserved aortic allografts for tracheal replacement
Number of subjects: 13
Study 37855022 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose multimatrix mesalamine (1800-4800 mg)
Number of subjects: 107
Study 37855022 — intervention group
Group type: COMPARATOR
Intervention: Low-dose multimatrix mesalamine (900-2400 mg)
Number of subjects: 107
Study 37855022 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment (both doses)
Number of subjects: 107
Study 37855023 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Challenge Inventory Tool (ICIT)
Number of subjects: 541
Study 37855023 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 541
Study 37855024 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovative Care (IC) with mental health specialist involvement
Number of subjects: 1379
Study 37855024 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 1379
Study 37855024 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovative Care (IC)
Number of subjects: 1379
Study 37855026 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled interferon-β1a (SNG001) given once daily for 14 days
Number of subjects: 220
Study 37855026 — intervention group
Group type: COMPARATOR
Intervention: Blinded pooled placebo
Number of subjects: 220
Study 37855029 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin
Number of subjects: 1045
Study 37855029 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 1045
Study 37855029 — intervention group
Group type: COMPARATOR
Intervention: Thrombocytopenia
Number of subjects: 1045
Study 37855069 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox granules
Number of subjects: 224
Study 37855069 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox dispersible tablets (DT)
Number of subjects: 224
Study 37855069 — intervention group
Group type: COMPARATOR
Intervention: Control (not applicable)
Number of subjects: 224
Study 37855117 — intervention group
Group type: EXPERIMENTAL
Intervention: High total MRCI scores (>7)
Number of subjects: 2853
Study 37855117 — intervention group
Group type: COMPARATOR
Intervention: Low total MRCI scores (≤7)
Number of subjects: 2853
Study 37855227 — intervention group
Group type: EXPERIMENTAL
Intervention: Shortened course of antibiotics
Number of subjects: 0
Study 37855227 — intervention group
Group type: COMPARATOR
Intervention: Standard course of antibiotics
Number of subjects: 0
Study 37855277 — intervention group
Group type: EXPERIMENTAL
Intervention: Online storytelling-based acceptance and commitment therapy (ACT)
Number of subjects: 0
Study 37855277 — intervention group
Group type: COMPARATOR
Intervention: Antidepressant treatment
Number of subjects: 0
Study 37855448 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab (420 mg subcutaneous injections monthly for 80 weeks)
Number of subjects: 100
Study 37855448 — intervention group
Group type: COMPARATOR
Intervention: Evolocumab (after 24 weeks of placebo)
Number of subjects: 100
Study 37855448 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab (after 24 weeks of evolocumab)
Number of subjects: 100
Study 37855688 — intervention group
Group type: EXPERIMENTAL
Intervention: loncastuximab tesirine
Number of subjects: 138
Study 37855706 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine filtration administered for 12 hours within the first 24 hours post-LTx
Number of subjects: 116
Study 37855706 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment with no cytokine filtration
Number of subjects: 116
Study 37855754 — intervention group
Group type: EXPERIMENTAL
Intervention: Mavacamten
Number of subjects: 251
Study 37855754 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study 37855898 — intervention group
Group type: EXPERIMENTAL
Intervention: 10° reverse Trendelenburg
Number of subjects: 167
Study 37855898 — intervention group
Group type: EXPERIMENTAL
Intervention: 20° reverse Trendelenburg
Number of subjects: 167
Study 37855898 — intervention group
Group type: COMPARATOR
Intervention: Standard lithotomy
Number of subjects: 167
Study 37855920 — intervention group
Group type: EXPERIMENTAL
Intervention: Free Gingival Graft (FGG)
Number of subjects: 38
Study 37855920 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertically Coronally Advanced Flap (V-CAF)
Number of subjects: 38
Study 37855920 — intervention group
Group type: COMPARATOR
Intervention: Both techniques (FGG and V-CAF)
Number of subjects: 38
Study 37855973 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Electrical Neuromodulation (REN)
Number of subjects: 409
Study 37856013 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfosbuvir plus Daclatasvir (600 mg alfosbuvir + 60 mg daclatasvir once daily for 12 weeks)
Number of subjects: 326
Study 37856106 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine (625 mg/m2 orally twice daily for 21 days), Oxaliplatin (130 mg/m2 intravenously), Pembrolizumab (200 mg intravenously), with optional Epirubicin (50 mg/m2 every 3 weeks); followed by maintenance Pembrolizumab (14 additional doses).
Number of subjects: 36
Study 37856126 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced suctioning via a battery-operated device
Number of subjects: 372
Study 37856126 — intervention group
Group type: COMPARATOR
Intervention: Minimal suctioning via bulb
Number of subjects: 372
Study 37856173 — intervention group
Group type: EXPERIMENTAL
Intervention: Sense2Quit App with 8-week supply of nicotine replacement therapy, standard smoking cessation counseling, and access to the Sense2Quit mobile app and smartwatch
Number of subjects: 60
Study 37856173 — intervention group
Group type: COMPARATOR
Intervention: Standard smoking cessation counseling and referral to the New York State Smokers' Quitline
Number of subjects: 60
Study 37856182 — intervention group
Group type: EXPERIMENTAL
Intervention: Interoceptive Exposure Technique (IET)
Number of subjects: 0
Study 37856182 — intervention group
Group type: COMPARATOR
Intervention: Control Group A (treatment as usual)
Number of subjects: 0
Study 37856182 — intervention group
Group type: COMPARATOR
Intervention: Control Group B (treatment as usual)
Number of subjects: 0
Study 37856188 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 different reward structures (with fixed and bonus components)
Number of subjects: 384
Study 37856188 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 different schedule lengths (7 or 14 days)
Number of subjects: 384
Study 37856188 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation strategy change (SMS text messages instead of emails)
Number of subjects: 384
Study 37856199 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGFR TKI therapy
Number of subjects: 987
Study 37856212 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal tumor debulking followed by systemic therapy
Number of subjects: 300
Study 37856212 — intervention group
Group type: COMPARATOR
Intervention: Standard systemic therapy alone
Number of subjects: 300
Study 37856212 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal tumor debulking
Number of subjects: 300
Study 37856212 — intervention group
Group type: EXPERIMENTAL
Intervention: Both study arms
Number of subjects: 300
Study 37856386 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally adapted hybrid version of the Incredible Years School Age Basic and Advance Programs delivered online, 12 weekly 2-hr sessions.
Number of subjects: 49
Study 37856386 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group receiving literature from the American Academy of Pediatrics' Bright Futures program.
Number of subjects: 49
Study 37856920 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/kg ARA and 50 mg/kg DHA supplementation
Number of subjects: 121
Study 37856920 — intervention group
Group type: COMPARATOR
Intervention: Medium chain triglycerides (control)
Number of subjects: 121
Study 37857068 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive leg raising (PLR) test
Number of subjects: 29
Study 37857068 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume expansion of 500 mL of crystalloid solution
Number of subjects: 29
Study 37857147 — intervention group
Group type: EXPERIMENTAL
Intervention: Saliva-based diagnostic signature using piRNA expression
Number of subjects: 200
Study 37857147 — intervention group
Group type: EXPERIMENTAL
Intervention: Differential expression of piRNAs in patients with hormonal treatment
Number of subjects: 200
Study 37857147 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of piRNA expression with age
Number of subjects: 200
Study 37857168 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) 20 mg/kg after induction (n=300)
Number of subjects: 600
Study 37857168 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control) (n=300)
Number of subjects: 600
Study 37857168 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA)
Number of subjects: 600
Study 37857168 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 600
Study 37857291 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate monotherapy
Number of subjects: 0
Study 37857291 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37857429 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrointestinal pirfenidone
Number of subjects: 0
Study 37857429 — intervention group
Group type: COMPARATOR
Intervention: Control group (diet not specified)
Number of subjects: 0
Study 37857496 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthostatic Hypotension (OH) in iRBD participants
Number of subjects: 340
Study 37857496 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced HR augmentation in OH participants
Number of subjects: 340
Study 37857496 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine hypertension (sHTN) in OH participants
Number of subjects: 340
Study 37857496 — intervention group
Group type: COMPARATOR
Intervention: Comparison of iRBD participants with and without OH
Number of subjects: 340
Study 37857620 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg ketamine
Number of subjects: 0
Study 37857620 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 mg/kg ketamine
Number of subjects: 0
Study 37857620 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37857710 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistant potato starch (RPS) daily from day -7 to day 100
Number of subjects: 10
Study 37857710 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistant potato starch (RPS)
Number of subjects: 10
Study 37857710 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 10
Study 37857711 — intervention group
Group type: EXPERIMENTAL
Intervention: Tebotelimab monotherapy (600 mg once every 2 weeks)
Number of subjects: 269
Study 37857711 — intervention group
Group type: EXPERIMENTAL
Intervention: Tebotelimab in combination with margetuximab
Number of subjects: 269
Study 37857766 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean BMI (per 1-SD increment)
Number of subjects: 1838
Study 37857766 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean systolic BP (per 1-SD increment)
Number of subjects: 1838
Study 37857766 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean diastolic BP (per 1-SD increment)
Number of subjects: 1838
Study 37857766 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean HDL-c (per 1-SD increment)
Number of subjects: 1838
Study 37857939 — intervention group
Group type: EXPERIMENTAL
Intervention: TXA administered at the beginning of induction (TXAI)
Number of subjects: 177
Study 37857939 — intervention group
Group type: EXPERIMENTAL
Intervention: TXA administered at the end of surgery (TXAP)
Number of subjects: 177
Study 37857939 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 177
Study 37857980 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram based on clinical factors and CE-CBBCT radiomics features
Number of subjects: 312
Study 37857980 — intervention group
Group type: COMPARATOR
Intervention: Clinical model
Number of subjects: 312
Study 37857980 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram
Number of subjects: 312
Study 37858005 — intervention group
Group type: EXPERIMENTAL
Intervention: Daridorexant 50 mg once daily
Number of subjects: 24
Study 37858005 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 24